Real-World Study of DLBCL With Different Genetic Subtypes
NCT06026488 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000
Last updated 2024-12-19
Summary
To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes
Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Lymphoma
Interventions
- OTHER
-
Other
real world treatment and survival of DLBCL patients in China
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-01
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- China
Study Locations
More Related Trials
-
A Real-World Study on Extranodal Lymphoma
NCT06573099 ·Status: NOT_YET_RECRUITING
-
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
NCT04425824 ·Status: UNKNOWN ·Phase: PHASE2
-
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
NCT06594432 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
NCT06669143 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Dynamic CtDNA-guided Targeted Therapy in DLBCL
NCT06748521 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
NCT06289959 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
NCT05200312 ·Status: UNKNOWN ·Phase: PHASE2
-
Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05318391 ·Status: COMPLETED
-
Reduced Chemotherapy in Low Risk DLBCL
NCT02752815 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
NCT05192486 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00244985 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research
NCT06049381 ·Status: NOT_YET_RECRUITING
-
Genotype-guided Treatment in DLBCL
NCT05351346 ·Status: RECRUITING ·Phase: PHASE3
-
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
NCT06005870 ·Status: RECRUITING ·Phase: PHASE2
-
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT01340443 ·Status: COMPLETED
-
The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.
NCT05428670 ·Status: UNKNOWN ·Phase: PHASE2
-
A Combination Study of CAR-T Therapy in r/r B-NHL
NCT05871684 ·Status: UNKNOWN ·Phase: PHASE2
-
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
NCT06503263 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase I/II Study of Diffuse Large B-cell Lymphoma
NCT04856137 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients
NCT04164368 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
NCT06760039 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
NCT02542111 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT01466868 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients
NCT01793844 ·Status: UNKNOWN
-
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
NCT06609304 ·Status: RECRUITING ·Phase: PHASE4